A total of 553 Private Equity/Venture Financing deals (pending and completed) were announced in the Healthcare of China, in the last twelve months resulting in a total deal value of over $24,899.7 million. In the LTM period, August 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $3,743.7 million, resulting in an average deal value of $63.5 million during that month. On the other hand, the month of December 2021 was the most prolific in terms of deal volume, recording a total of 64 deals, resulting in an average deal value of $57.5 million during that month.
Of the 553 deals, the deal secured between FountainVest Partners and Beijing Zhendong Langdi Pharmaceutical Co Ltd, was the largest Private Equity/Venture Financing deal in the China Healthcare sector, which was valued at $900.0 million and was completed on November 19, 2021. The second-largest deal was between 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital and Suzhou Abogen Biosciences Co Ltd, while the third-largest deal was between China Investment China Finance Fund; Sequoia China Investment Management LLP; Tencent Holdings Ltd and Medlinker. The 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital-Suzhou Abogen Biosciences Co Ltd deal and the China Investment China Finance Fund; Sequoia China Investment Management LLP; Tencent Holdings Ltd-Medlinker deal were valued at $700.0 million and $514.0 million, respectively. The fourth-largest deal was between ABC International Holdings Limited; Aobo Capital; BOCOM International Holdings Company Limited; Country Garden Venture Capital; General Atlantic LLC; Hudson Bay Capital Management LP; ICBC International Holdings Ltd; Legend Capital Co Ltd; Primavera Capital Group; Taikang Life Insurance Co., Ltd.-Hong Kong Asia Medical Holding Ltd; Jingtai Technology valued at $400.0 million, whereas the deal between Hillhouse Capital Group-Shanghai Asymchem Biotechnology Development valued at $392.6 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $2,914.0 million and accounted for nearly 11.70% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
United States of America
Japan
Ireland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward